Galera Therapeutics

Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial

MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX)  announced that a prespecified analysis from the Phase 3 ROMAN trial detailing one-year reductions in cisplatin-related chronic kidney disease in patients with …

Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial Read More




Appluent

Appluent Unveils FilePulse 360 and Learning Xperience to Celebrate 10 Years, Wins Conga Partner Impact Award

PHOENIXVILLE, PA — Appluent Business Solutionsâ„¢ is celebrating its 10th anniversary by launching two new products, FilePulse 360, and the Learning Xperience. In addition, the company was honored with the Conga® Partner Impact …

Appluent Unveils FilePulse 360 and Learning Xperience to Celebrate 10 Years, Wins Conga Partner Impact Award Read More